

Position Statement; Prescribing of dapoxetine for premature ejaculation is not supported.

Castle Point and Rochford and Southend Clinical Commissioning Groups do not support the prescribing of dapoxetine (Priligy®) for the treatment of premature ejaculation (PE) as it is not a cost effective option.

- Dapoxetine is a short acting selective serotonin re-uptake inhibitor licensed for use in the treatment of premature ejaculation in men aged between 18 – 64 years who meet all of the following criteria;
 - An intravaginal ejaculatory latency time (IELT) of less than two minutes; and
 - Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and
 - Marked personal distress or interpersonal difficulty as a consequence of PE; and poor control over ejaculation; and
 - A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.
- The East of England Priorities Advisory Committee has advised that commissioning of dapoxetine is low priority and is not recommended.
- The cost of dapoxetine is significantly more than SSRIs used off license currently.
- Long term safety data is not available.
- There were a number of limitations with the five dapoxetine clinical trials;
 - The effects of dapoxetine on erectile dysfunction were not assessed. PE is often associated with erectile dysfunction.
 - Only men in stable, monogamous, heterosexual relationships were included in the studies.
 - No active comparators were studied, all studies were against placebo. This may reflect the fact that no other oral therapies are licensed for premature ejaculation.
 - Only just over half of those enrolled completed study NCT00229073 (21% of the dapoxetine group and 31% of the placebo groups discontinuing by choice).

Providers commissioned to provide services on behalf of Castle Point and Rochford and Southend CCGs are reminded that they are required to follow the Castle Point and Rochford and Southend CCGs formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification). See Southend and Castle Point and Rochford CCGs websites – Medicines management for all prescribing guidance.

Reviewed and adapted for use from Mid Essex CCG Prescribing Policy Statements

Approved for use in Castle Point & Rochford and Southend CCGs	Drugs and Therapeutics Committee 1 st March 2017
Title	Dapoxetine (Priligy®) v1.0
Reference	East of England Priorities Advisory Committee guidance, March 2014 .